KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

• Main Authors: Omar S. Al-Odat (Author), Weam Othman Elbezanti (Author), Krishne Gowda (Author), Sandeep K. Srivastava (Author), Shantu G. Amin (Author), Subash C. Jonnalagadda (Author), Tulin Budak-Alpdogan (Author), Manoj K. Pandey (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and almost all patients relapse. Poor patient outcomes demonstrate that myeloma cells are "born to survive" which me...